In 2021, RELX continued to build on our strong corporate responsibility (CR) performance during the year, further improving on our key internal metrics and extending the scope of our unique contributions. This article is linked to SDGs 1,3,10,11,12,13 and 16, in line with RELX's areas of expertise.
The Lancet, Volume 400, Issue 10368, 10–16 December 2022, Pages 2137-2146
This Series paper supports SDGs 3 and 10 by focusing on wider societal action to confront the health effects of racism, highlighting that broader, deeper, transformative action is needed compared with current measures to tackle the adverse effects of racism on health.
Viral Infections and Antiviral Therapies
2023, Pages 85-98
This content supports the SDG Goal 3: Good health and well-being by discussing sexually transmitted diseases caused by viruses including genital warts, genital herpes, the human immunodeficiency virus, human T cell lymphotropic virus, and hepatitis A, B, C.